D1064
Dihydrokainic acid
≥98% (HPLC), GLT-1 glutamate transporter inhibitor, powder
Synonym(s):
2-Carboxy-4-isopropyl-3-pyrrolidineacetic acid
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C10H17NO4
CAS Number:
Molecular Weight:
215.25
UNSPSC Code:
12352106
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Product Name
Dihydrokainic acid, ≥98% (HPLC), powder
Quality Level
assay
≥98% (HPLC)
form
powder
solubility
H2O: >10 mg/mL
storage temp.
2-8°C
SMILES string
CC(C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O
InChI
1S/C10H17NO4/c1-5(2)7-4-11-9(10(14)15)6(7)3-8(12)13/h5-7,9,11H,3-4H2,1-2H3,(H,12,13)(H,14,15)/t6-,7+,9-/m0/s1
InChI key
JQPDCKOQOOQUSC-OOZYFLPDSA-N
Gene Information
human ... SLC1A1(6505), SLC1A2(6506), SLC1A3(6507)
rat ... Slc1a2(29482), Slc1a3(29483)
Application
Dihydrokainic acid has been used as a glutamate transporter (GLT-1) inhibitor in the glutamate uptake assay of astrocytes and glial cells. It may be used as a GLT-1 inhibitor in Lateral habenula (LHb).
Biochem/physiol Actions
Dihydrokainic favors neuronal cell death. It modulates anxiety and depression behaviors.
Dihydrokainic acid is a selective GLT-1 glutamate transporter inhibitor; weak inhibitor of AMPA/kainate glutamic acid receptors at high concentrations.
Dihydrokainic acid is a selective inhibitor of the GLT-1 glutamate transporter. At higher concentrations, dihydrokainate is a weak inhibitor of AMPA/kainate glutamic acid receptors.
Features and Benefits
This compound is featured on the Excitatory Amino Acid Transporters page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Rescue of glutamate transport in the lateral habenula alleviates depression-and anxiety-like behaviors in ethanol-withdrawn rats
Kang S, et al.
Neuropharmacology, 129(11), 47-56 (2018)
Scott M Rawls et al.
Drug and alcohol dependence, 107(2-3), 261-263 (2009-12-17)
Glutamate transporter subtype 1 (GLT-1) activation is a promising - and understudied - approach for managing aspects of morphine tolerance caused by increased glutamatergic transmission. Identification of beta-lactam antibiotics as pharmaceuticals which activate GLT-1 transporters prompted us to hypothesize that
Anita J Bechtholt-Gompf et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 35(10), 2049-2059 (2010-06-10)
Mood disorders are associated with regional brain abnormalities, including reductions in glial cell and neuron number, glutamatergic irregularities, and differential patterns of brain activation. Because astrocytes are modulators of neuronal activity and are important in trafficking the excitatory neurotransmitter glutamate
Global Trade Item Number
| SKU | GTIN |
|---|---|
| D1064-10MG | 04061833558492 |
| D1064-50MG | 04061832081830 |